ペプチド治療薬の世界市場2019-2023...市場調査レポートについてご紹介

【英文タイトル】Global Peptide Therapeutics Market 2019-2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY ROA
• Market segmentation by RoA
• Comparison by RoA
• Parenteral – Market size and forecast 2018-2023
• Oral – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by RoA
PART 07: MARKET SEGMENTATION BY INDICATION
PART 08: MARKET SEGMENTATION BY TECHNOLOGY
PART 09: CUSTOMER LANDSCAPE
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Eli Lilly
• Novo Nordisk
• Sanofi
• Takeda Pharmaceutical
• Teva Pharmaceutical
PART 15: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: RoA – Market share 2018-2023 (%)
Exhibit 19: Comparison by RoA
Exhibit 20: Parenteral – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Parenteral – Year-over-year growth 2019-2023 (%)
Exhibit 22: Oral – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Oral – Year-over-year growth 2019-2023 (%)
Exhibit 24: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Others – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by RoA
Exhibit 27: Market share by 2018-2023 (%)
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 33: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 35: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Eli Lilly – Vendor overview
Exhibit 47: Eli Lilly – Business segments
Exhibit 48: Eli Lilly – Organizational developments
Exhibit 49: Eli Lilly – Geographic focus
Exhibit 50: Eli Lilly – Segment focus
Exhibit 51: Eli Lilly – Key offerings
Exhibit 52: Eli Lilly – Key customers
Exhibit 53: Novo Nordisk – Vendor overview
Exhibit 54: Novo Nordisk – Business segments
Exhibit 55: Novo Nordisk – Organizational developments
Exhibit 56: Novo Nordisk – Geographic focus
Exhibit 57: Novo Nordisk – Segment focus
Exhibit 58: Novo Nordisk – Key offerings
Exhibit 59: Novo Nordisk – Key customers
Exhibit 60: Sanofi – Vendor overview
Exhibit 61: Sanofi – Business segments
Exhibit 62: Sanofi – Organizational developments
Exhibit 63: Sanofi – Geographic focus
Exhibit 64: Sanofi – Segment focus
Exhibit 65: Sanofi – Key offerings
Exhibit 66: Sanofi – Key customers
Exhibit 67: Takeda Pharmaceutical – Vendor overview
Exhibit 68: Takeda Pharmaceutical – Business segments
Exhibit 69: Takeda Pharmaceutical – Organizational developments
Exhibit 70: Takeda Pharmaceutical – Geographic focus
Exhibit 71: Takeda Pharmaceutical – Key offerings
Exhibit 72: Takeda Pharmaceutical – Key customers
Exhibit 73: Teva Pharmaceutical – Vendor overview
Exhibit 74: Teva Pharmaceutical – Business segments
Exhibit 75: Teva Pharmaceutical – Organizational developments
Exhibit 76: Teva Pharmaceutical – Geographic focus
Exhibit 77: Teva Pharmaceutical – Segment focus
Exhibit 78: Teva Pharmaceutical – Key offerings
Exhibit 79: Teva Pharmaceutical – Key customers
Exhibit 80: Validation techniques employed for market sizing
Exhibit 81: List of abbreviations


【レポート販売概要】

■ タイトル:ペプチド治療薬の世界市場2019-2023
■ 英文:Global Peptide Therapeutics Market 2019-2023
■ 発行日:2018年12月24日
■ 調査会社:Technavio
■ 商品コード:IRTNTR30538
■ 調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。